Literature DB >> 19674285

Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis.

K E Corey1, J Mendez-Navarro, E C Gorospe, H Zheng, R T Chung.   

Abstract

Acute hepatitis C virus infection is associated with high rates of spontaneous clearance and variable rates of treatment-induced clearance. The benefit of early treatment versus awaiting spontaneous clearance is unknown, as is the optimal timing of treatment.We performed a MEDLINE and EMBASE search for the time period 1950 to October 2008. All English language abstracts using the search terms acute hepatitis C, hepatitis C and acute and hepatitis C and acute disease or acute infection were reviewed. Bibliographies were reviewed.Twenty-two studies including 1075 patients met the inclusion criteria. The sustained virologic response (SVR) rate for treated patients was 78%, significantly higher than 55.1% in untreated patients (OR = 3.08, 95% CI: 1.8-4.8 P value <0.0001). Mean time from diagnosis to spontaneous clearance was 9.7 weeks (SD 6.5). SVR rates varied inversely with time from acute HCV diagnosis. SVR rates for treatment within 12 weeks was 82.5% (95% CI: 75.6-89.3), significantly better than the clearance rates in untreated patients (P < 0.001). Response rates fell to 66.9% for treatment between 12 and 24 weeks, and decreased further to 62.5% for treatment beyond 24 weeks. Rates of viral clearance in treated patients with acute hepatitis C virus infection were significantly higher than that in untreated patients. Treatment rates were highest when treatment was initiated within 12 weeks of diagnosis. Based on these findings, we would advocate a 12 week period of observation for spontaneous clearance before treatment initiation. If no clearance has occurred by 12 weeks, treatment should be initiated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19674285      PMCID: PMC3769693          DOI: 10.1111/j.1365-2893.2009.01167.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  28 in total

1.  Natural course of acute hepatitis C: a long-term prospective study.

Authors:  T Santantonio; E Sinisi; A Guastadisegni; C Casalino; M Mazzola; A Gentile; G Leandro; G Pastore
Journal:  Dig Liver Dis       Date:  2003-02       Impact factor: 4.088

2.  Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial.

Authors:  Hideyuki Nomura; Suketo Sou; Hironori Tanimoto; Takashi Nagahama; Yoichi Kimura; Jun Hayashi; Hiromi Ishibashi; Seizaburo Kashiwagi
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

3.  The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.

Authors:  G L Armstrong; M J Alter; G M McQuillan; H S Margolis
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

4.  Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies.

Authors:  Alberto Larghi; Massimo Zuin; Andrea Crosignani; Maria Lisa Ribero; Cristina Pipia; Pier Maria Battezzati; Giorgio Binelli; Francesco Donato; Alessandro Remo Zanetti; Mauro Podda; Alessandro Tagger
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

Review 5.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

6.  Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C.

Authors:  S J Hwang; S D Lee; R H Lu; C W Chu; J C Wu; S T Lai; F Y Chang
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

7.  Treatment of acute hepatitis C with interferon alfa-2b.

Authors:  E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

8.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

Authors:  J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

Review 9.  Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha.

Authors:  Johannes Wiegand; Katja Deterding; Markus Cornberg; Heiner Wedemeyer
Journal:  J Antimicrob Chemother       Date:  2008-09-05       Impact factor: 5.790

10.  Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.

Authors:  Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  27 in total

1.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 3.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

4.  Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report.

Authors:  Alice Asher; Paula J Lum; Kimberly Page
Journal:  J Assoc Nurses AIDS Care       Date:  2011-04-15       Impact factor: 1.354

Review 5.  Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.

Authors:  E Sagnelli; T Santantonio; N Coppola; M Fasano; M Pisaturo; C Sagnelli
Journal:  Infection       Date:  2014-03-12       Impact factor: 3.553

Review 6.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

7.  The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes.

Authors:  R Loomba; M M Rivera; R McBurney; Y Park; V Haynes-Williams; B Rehermann; H J Alter; S K Herrine; T J Liang; J H Hoofnagle; T Heller
Journal:  Aliment Pharmacol Ther       Date:  2010-12-29       Impact factor: 8.171

8.  Acute hepatitis C: to treat or not to treat.

Authors:  Niharika R Samala; Marc G Ghany
Journal:  Lancet Infect Dis       Date:  2013-03-22       Impact factor: 25.071

9.  Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.

Authors:  Rania A Tohme; Jian Xing; Youlian Liao; Scott D Holmberg
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

10.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.